BCAX241115C17500
- 0.00
- 0.000.00%
Bicara Therapeutics Newsroom
Rodman & Renshaw Initiates Bicara Therapeutics(BCAX.US) With Buy Rating, Announces Target Price $48
Top Small-cap Stock Picks From Morgan Stanley Following the Group's Upgrade to Neutral
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Cantor Fitzgerald Initiates Coverage on Bicara Therapeutics With Overweight Rating
Bicara Therapeutics Analyst Ratings
TD Cowen Initiates Bicara Therapeutics(BCAX.US) With Buy Rating
Stifel Initiates Bicara Therapeutics(BCAX.US) With Buy Rating, Announces Target Price $47
Morgan Stanley Initiates Bicara Therapeutics(BCAX.US) With Buy Rating, Announces Target Price $35
Bicara Therapeutics: A Buy Rating on Promising Clinical Progress and Financial Fortitude
Bicara Therapeutics Initiated With an Overweight at Morgan StanleyMerus
Three Biotech Startups Plan $400 Million U.S. IPOs Amid Sector Resurgence
Bicara Therapeutics, Adecoagro, and More Stocks See Action From Activist Investors -- Barrons.com
Biotech IPOs Return as Sector Recovers After Funding Overhang
Express News | Ra Capital Management LP Reports 12.8% Stake in Bicara Therapeutics as of Sept 16 - SEC Filing
FMR LLC Acquires New Stake in Bicara Therapeutics Inc
Bicara Therapeutics Insider Bought Shares Worth $1,260,000, According to a Recent SEC Filing
Deerfield Entities Buy Bicara Therapeutics Shares Worth $1.26m
Bicara Therapeutics Shares Began Trading on Nasdaq Global Market on Sept 13 Under Ticker BCAX
Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Biotech IPO Shares Climb in Debuts After Deals Upsized